China Pharmaceuticals Industry Performance After the Virus Outbreak and An Outlook to 2027

China Pharmaceuticals Industry Performance After the Virus Outbreak and An Outlook to 2027

Executive Summary

Market Facts
Globally, China is placed as the largest producer of Pharmaceutical compounds.The country's Pharmaceutical sales are mostly influenced by the nation’s growing aging population, increasing healthcare awareness among people, and rising overall and per capita healthcare expenditures.
China is the world's largest manufacturer of active pharmaceutical ingredients (APIs) however As compared to the other developed nations, China's healthcare expenditure including drugs is much low. In China, generic drugs account for more than 85.4% of all drugs registered thus has a dominance over the market. Prescription drug sales outperformed over OTC drug sales after the outbreak of coronavirus.

Report titled “China Pharmaceuticals Industry Performance After the Virus Outbreak and An Outlook to 2027” gives detailed analysis of the industry performance considering the past, present and future trends with a detailed discussion of macro economic factors that plays a major role. An overview of the Healthcare sector has been covered in the report to highlight opportunities present for the pharmaceuticals in the country. Regulatory overview has been covered in the report that carries key regulations and initiatives taken by the government to uplift the sector. The report provides a comprehensive analysis of the Pharmaceuticals market that describes market by expenditures and further segmented into Generic and Patented Drugs, Prescription and OTC Drugs. OTC drugs market performance covers past, present and future outlook. Competitive landscape cover major M&A deals happened in the past and company profiles of the major players operating in the market.

Market Performance: From diagnosing, curing to treating, the Pharmaceuticals play a vital role in the global health system. China's pharmaceutical industry has witnessed rapid growth since joining the World Trade Organization. In the last few decades, the massive growth of the sector has enabled the country to become the second-largest pharmaceutical market in the world. Therefore, China has firmly established itself as a key player in the Global pharmaceutical market. Due to lower manufacturing costs, availability of cheap and skilled labor and a favorable regulatory environment has given boost to the domestic and international players operating in the market.

COVID-19 Impact : The outbreak of pandemic left a mixed impact over the country’s pharmaceutical industry. Pandemic boosted the digital pharmacy as well as E-consulting services. During the first quarter of 2020, firms witnessed rise in demand for drug products, However, this correlated with a decrease in the supply of APIs due to the closure of several factories in China.

Competitive Landscape: This section cover company profile and mergers and acquisitions covering key players including:
Shanghai Pharmaceuticals Group Co. Ltd, China Resources Pharmaceutical Group Co., Ltd, Guangzhou Baiyunshan Pharmaceutical Group Co. Ltd, Sinopharm Group, Huadong Pharmaceutical Co., Yunnan Baiyao Group Co., Ltd.,

Key Questions Answered
What is current scenario of the China pharmaceuticals industry and its positioning in the global market?
How China is dealing with the COVID-19 crisis and how its healthcare system is placed to deal with the present scenario?
What are the key segmentations of the industry and how these segments are performing?
How OTC market performed in the past and what is the expected future outlook of the sector?
How Generic drugs are placed in the market and what is expected growth in the near future?
What are the key regulations in the market and government measures to uplift the market?
What are the key challenges present in the market also what are the major macro economic factors and how these factors are performing?
Who are the leading players operating in the pharmaceuticals market and their financial situation?